# A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia

> **NCT07428486** · PHASE1 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Phase I
- FLAG Chemotherapy
- Lisaftoclax
- Pelcitoclax
- Relapsed/Refractory
- Lymphoblastic Leukemia Acute

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** G-CSF
- **DRUG:** Lisaftoclax
- **DRUG:** Pelcitoclax

## Key facts

- **NCT ID:** NCT07428486
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-04-27
- **Primary completion:** 2026-04-27
- **Final completion:** 2026-04-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** PI requested
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07428486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07428486, "A Phase 1 Study Of FLAG Chemotherapy In Combination With Lisaftoclax And Pelcitoclax In Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT07428486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*